Home › Mild Cognitive Impairment › NCT04765137
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RecruitingPhase 2Healthy volunteers welcome
Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin
Who can join
Ages 60 to 95 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors: * MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0. * Memory, processing speed, executive function, language - cognitive scores \> 1.5 standard deviations below age-education norms. * Not demented by history. * Not taking statins currently or in the last 6 months. * Cognitive/functional impairment not likely due to another neurological disease or delirium. Exclusion Criteria: * Taking a statin currently or have taken a statin in the last 6 months. * Contraindications to taking a statin. * Transplant patient taking cyclosporine. * Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal). * Diagnosis of dementia by history. * Current diagnosis of substance abuse. * History of stroke or myocardial infarction in past 6 months. * History of HIV.
About the study
The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
What is being tested
- Atorvastatin Oral Tablet (drug)
Sponsor: Johns Hopkins University · Participants: 20 · Started: May 21, 2021
Contact the study team
- Samantha Horn · Phone: 410-550-9020
- Ritu Agarwal · Phone: 410-550-9020
Official record on ClinicalTrials.gov — NCT04765137
Locations in the U.S.
| Maryland | Johns Hopkins University, Bayview Medical Center, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.